AI Article Synopsis
- The theory that testosterone supplementation therapy (TST) might increase prostate volume and worsen lower urinary tract symptoms (LUTS) is being challenged by new findings.
- Recent studies suggest that TST does not significantly increase prostate size in patients with late-onset hypogonadism (LOH) and may even improve LUTS.
- Both testosterone deficiency and metabolic syndrome are linked to LUTS, but TST shows potential benefits, especially for patients with higher initial LUTS scores or those with metabolic syndrome, indicating the need for further research on TST's role.
Article Abstract
The theory that prostate growth depends on androgens has caused the worry clinically that the testosterone supplementation therapy (TST) may increase the prostate volume and worsen lower urinary tract symptoms (LUTS). However, more and more findings show that TST does not increase the prostate volume in patients with late-onset hypogonadism (LOH) or affect the IPSS, which may be attributed to the saturation of the androgen receptor. Testosterone deficiency and metabolic syndrome are risk factors for LUTS, the former affecting the autonomic nerve function, relaxation and blood supply of the bladder and urethral smooth muscle, and Rho enzyme activity, while the latter enhancing sympathetic activity and causing the body's inflammatory state and arteriosclerosis. Findings have proved that TST can improve LUTS in patients with LOH, with even better effect in those with a higher baseline IPSS or metabolic syndrome. More researches are needed to confirm the role of TST in improving LUTS.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!